Evaluating budesonide efficacy in nasal polyposis and predicting the resistance to treatment
Article first published online: 5 DEC 2008
© 2008 The Authors. Journal compilation © 2008 Blackwell Publishing Ltd
Clinical & Experimental Allergy
Volume 39, Issue 1, pages 81–88, January 2009
How to Cite
Valera, F. C. P., Queiroz, R., Scrideli, C., Tone, L.G. and Anselmo-Lima, W. T. (2009), Evaluating budesonide efficacy in nasal polyposis and predicting the resistance to treatment. Clinical & Experimental Allergy, 39: 81–88. doi: 10.1111/j.1365-2222.2008.03144.x
- Issue published online: 6 JAN 2009
- Article first published online: 5 DEC 2008
- Submitted 9 June 2008; revised 2 September 2008; accepted 2 October 2008
- nasal polyposis;
- transcription factor
Background Cell resistance to glucocorticoids is a major problem in the treatment of nasal polyposis (NP).
Objectives The objectives of this study were to observe the effect of budesonide on the expression of IL-1β, TNF-α, granulocyte macrophage-colony stimulating factor, intercellular adhesion molecule (ICAM)-1, basic fibroblast growth factor, eotaxin-2, glucocorticoid receptor (GR)-α, GR-β, c-Fos and p65 in nasal polyps and to correlate their expression to clinical response.
Methods Biopsies from nasal polyps were obtained from 20 patients before and after treatment with topical budesonide. Clinical response to treatment was monitored by a questionnaire and nasal endoscopy. The mRNA levels of the studied genes were measured by real-time quantitative (RQ)-PCR.
Results There was a significant decrease in the expression of TNF-α (P<0.05), eotaxin-2 (P<0.05) and p65 (P<0.05) in NP after treatment. Poor responders to glucocorticoids showed higher expression of IL-1β (3.74 vs. 0.14; P<0.005), ICAM-1 (1.91 vs. 0.29; P<0.05) and p65 (0.70 vs. 0.16; P<0.05) before treatment. Following treatment, IL-1β (4.18 vs. 0.42; P<0.005) and GR-β (0.95 vs. 0.28; P<0.05) mRNA expression was higher in this group.
Conclusion Topical budesonide reduced the expression of TNF-α, eotaxin-2 and p65. Poor responders to topical budesonide exhibit higher levels of IL-1β, ICAM-1 and nuclear factor (NF)-κB at diagnosis and higher expression of both IL-1β and GR-β after treatment. These results emphasize the anti-inflammatory action of topical budesonide at the molecular level and its importance in the treatment of NP. Nevertheless, IL-1β, ICAM-1 and NF-κB may be associated with primary resistance to glucocorticoids in NP, whereas higher expression of GR-β in poor responders only after glucocorticoid treatment may represent a secondary drug resistance mechanism in this disease.